308 related articles for article (PubMed ID: 26440127)
1. Immune responses to human cancer stem-like cells/cancer-initiating cells.
Hirohashi Y; Torigoe T; Tsukahara T; Kanaseki T; Kochin V; Sato N
Cancer Sci; 2016 Jan; 107(1):12-7. PubMed ID: 26440127
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.
Morita R; Nishizawa S; Torigoe T; Takahashi A; Tamura Y; Tsukahara T; Kanaseki T; Sokolovskaya A; Kochin V; Kondo T; Hashino S; Asaka M; Hara I; Hirohashi Y; Sato N
Cancer Sci; 2014 Apr; 105(4):389-95. PubMed ID: 24450541
[TBL] [Abstract][Full Text] [Related]
3. [Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy].
Miyamoto S; Kanaseki T; Hirohashi Y; Tsukahara T; Kikuchi Y; Sato N; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):40-47. PubMed ID: 28539553
[TBL] [Abstract][Full Text] [Related]
4. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.
Hirohashi Y; Torigoe T; Inoda S; Takahashi A; Morita R; Nishizawa S; Tamura Y; Suzuki H; Toyota M; Sato N
Immunotherapy; 2010 Mar; 2(2):201-11. PubMed ID: 20635928
[TBL] [Abstract][Full Text] [Related]
5. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
[TBL] [Abstract][Full Text] [Related]
6. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
7. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.
Pan Q; Li Q; Liu S; Ning N; Zhang X; Xu Y; Chang AE; Wicha MS
Stem Cells; 2015 Jul; 33(7):2085-92. PubMed ID: 25873269
[TBL] [Abstract][Full Text] [Related]
8. Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.
Mori T; Nishizawa S; Hirohashi Y; Torigoe T; Tamura Y; Takahashi A; Kochin V; Fujii R; Kondo T; Greene MI; Hara I; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):27-32. PubMed ID: 22001602
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity.
Albini A; Bruno A; Gallo C; Pajardi G; Noonan DM; Dallaglio K
Connect Tissue Res; 2015; 56(5):414-25. PubMed ID: 26291921
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
11. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma.
Kano M; Tsukahara T; Emori M; Murase M; Torigoe T; Kawaguchi S; Wada T; Yamashita T; Sato N
Cancer Sci; 2011 Aug; 102(8):1443-7. PubMed ID: 21518139
[TBL] [Abstract][Full Text] [Related]
12. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
[TBL] [Abstract][Full Text] [Related]
13. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cells: Regulation programs, immunological properties and immunotherapy.
Zhang D; Tang DG; Rycaj K
Semin Cancer Biol; 2018 Oct; 52(Pt 2):94-106. PubMed ID: 29752993
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.
Ruiu R; Tarone L; Rolih V; Barutello G; Bolli E; Riccardo F; Cavallo F; Conti L
Prog Mol Biol Transl Sci; 2019; 164():119-188. PubMed ID: 31383404
[TBL] [Abstract][Full Text] [Related]
16. A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties.
Mahmoodi S; Nezafat N; Negahdaripour M; Ghasemi Y
Curr Mol Med; 2019; 19(1):2-11. PubMed ID: 30714514
[TBL] [Abstract][Full Text] [Related]
17. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
[TBL] [Abstract][Full Text] [Related]
18. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H; Hirohashi Y; Yamada S; Yanagawa J; Murai A; Hashimoto S; Tokita S; Hori K; Abe T; Kubo T; Tsukahara T; Kanaseki T; Shinohara N; Torigoe T
Cancer Immunol Immunother; 2022 Apr; 71(4):795-806. PubMed ID: 34405274
[TBL] [Abstract][Full Text] [Related]
19. Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.
Takeda R; Hirohashi Y; Shen M; Wang L; Ogawa T; Murai A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nishidate T; Okita K; Kutomi G; Sato N; Takemasa I; Torigoe T
Biochem Biophys Res Commun; 2017 Apr; 485(3):651-657. PubMed ID: 28219643
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer stem cell antigens as targets for immunotherapy.
Quaglino E; Conti L; Cavallo F
Semin Immunol; 2020 Feb; 47():101386. PubMed ID: 31932198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
